Clinical Characteristics and CD4⁺ T Cell Subsets in IgG4-Related Disease

Yan Yang¹, Chen Wang², Lei Shi¹, Shuoran Yang³, Yan Liu¹, Jing Luo⁴ and Caihong Wang¹*

¹ Department of Rheumatology and Immunology, The Second Hospital of Shanxi Medical University, Taiyuan, China,
² Department of Pathology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³ Department of Oral and Maxillofacial Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴ Department of Rheumatology Laboratory, The Second Hospital of Shanxi Medical University, Taiyuan, China

Objectives: To characterize the clinical features of IgG4-related disease (IgG4-RD) and analyze the peripheral T lymphocyte subsets and cytokine levels.

Methods: A total of 52 patients with newly diagnosed IgG4-RD were enrolled in the retrospective study. Baseline clinical characteristics and examinational findings were systematically reviewed.

Results: IgG4-RD patients had a male predominance, with an average age of 57.4 ± 10.3 years (range 27-81). The mean number of involved organs was 2.7 (range 1-8). Submandibular gland (57.7%) and lacrimal gland/orbit (40.4%) were the most commonly involved organs. Serum IgG4 increased in 97.9% of the patients, the median level was 1300 (585.25, 1975) mg/dl. Decreased C3 and C4 accounted for 77.8% and 55.6% of this patient cohort, respectively. Receiver operating characteristic (ROC) test indicated the possibility of lung/pleura involvement when C3 was less than 0.570 g/l (AUC = 0.788, P = 0.014), and kidney involvement when C3 was less than 0.545 g/l (AUC = 0.796, P = 0.014). Compared with healthy controls (HC), the absolute Th1 counts were higher in IgG4-RD patients (157.58 cells/µl vs. 130.54 cells/µl, P = 0.038), while the absolute counts of Th2, Th17 and T regulatory (Treg) cells, as well as Th17/Treg ratio were not statistically different. The levels of serum IL-4, IL-6, IL-17, TNF-α, and IFN-γ were higher in patients with IgG4-RD as compared with HC (P < 0.001). Serum IL-10 was positively correlated with IL-4, TNF-α and IFN-γ, but uncorrelated with Treg cells. Serum IgG4 level was positively associated with the number of affected organs, eosinophil counts, and ESR, whereas inversely associated with C3, C4, IgM, and IgA.

Conclusion: Submandibular and lacrimal glands are the most commonly involved organs in IgG4-RD. Serum C3 level could be a predictor of lung/pleura and kidney involvement in the disease process. Elevated Th1 cells are probably related to chronic inflammation and fibrosis. Treg cells are unlikely to play an important role in the pathogenesis of IgG4-RD.

Keywords: IgG4-related disease, atopy, eosinophils, CD4⁺ T cell subsets, cytokines
INTRODUCTION

IgG4-related disease (IgG4-RD) is an immune-mediated chronic fibro-inflammatory disease characterized by enlargement and sclerosis of affected organs, compression of the surrounding tissues, and ultimately leads to tissue destruction and organ failure. Dense lymphocytic infiltration, especially dramatic IgG4+ plasma cells, and storiform fibrosis are the significant pathological features of the disease (1–3).

It is a highly heterogeneous disease that can affect virtually all organs, and the clinical manifestations are protean. Pancreas, bile duct, lacrimal and salivary glands, orbital and retroperitoneal tissues are the commonly affected sites. In addition, IgG4-RD is an excellent imitator, which is easily confused with malignancy, infection, and other immune-mediated conditions, and likely to result in misdiagnosis or even over-diagnosis. Thus, the accurate diagnosis of IgG4-RD is highly dependent on the comprehensive analyses of clinical features, laboratory findings, imaging examinations, and histopathological manifestations.

In this study, we compared demographic characteristics and recorded the laboratory parameters of 52 IgG4-RD patients, and simultaneously analyzed peripheral lymphocyte subgroups, CD4+ T cell subsets, and serum cytokines. We expect these data would improve the understanding of IgG4-RD and provide a reference for exploring pathogenesis and therapeutic targets.

MATERIALS AND METHODS

Patient Enrollment

This retrospective observational study enrolled 52 patients with IgG4-RD referred to the Second Hospital of Shanxi Medical University from November 2015 to January 2021. According to the classification criteria for IgG4-RD formulated by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) in 2019 (4), the newly diagnosed and untreated patients were classified following a sequentially three-step that consist of entry criterion, exclusion criterion and inclusion criteria. This study was approved by the Medical Ethics Committee of the second hospital of Shanxi Medical University (Shanxi, China).

Patient Characteristics and Examination Parameters

Patient characteristics including age at diagnosis, gender, disease duration, and atopic history were recorded, along with clinical, radiologic, laboratory, and pathologic data obtained at the time of presentation. The HC consisted of 50 healthy volunteers with gender and age matched during the same period. Atopic history was collected according to the definitions of the European Academy of Allergy and Clinical Immunology (EAACI) (5).

Laboratory data comprised blood count, liver and renal function, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complement (C3, C4). Serum immunoglobulin (IgG, IgA, and IgM) and IgG subclasses (IgG1, IgG2, IgG3, and IgG4) were detected by immunoturbidimetry. Rheumatoid factor (RF) was determined by enzyme-linked immunosorbent assay (ELISA), anti-nuclear antibody (ANA) and anti-extractable nuclear antibodies (anti-ENAs) were measured by indirect immunofluorescence assay (IFA) and western blotting, respectively.

Immunophenotypes of lymphocyte subsets were determined by FACSCalibur (BD Biosciences). All immunofluorescence antibodies were purchased from BD Biosciences. The absolute counts of peripheral lymphocyte subgroups (CD3+ T/CD4+ T/CD8+ T/CD19+ B/NK cells) were analyzed by BD MultiSET software and FACSCanto II (BD Immunocytometry Systems, USA). For CD4+ T cell subsets (Th1/Th2/Th17/Treg cells), we needed to gate on CD4+ T cells initially. First, we added Ionomycin, PMA, and GolgiStop into 200μl heparin-anticoagulated venous blood to stimulate cells. Second, cells were labeled by CD4-FITC, followed by 2ml freshly prepared Fixation/Permeabilization. Finally, we stained cells using IFN-γ-APC/IL-4-PE/IL-17-PE to identify Th1/Th2/Th17 cells. Treg cells in 80μl heparin-anticoagulated venous blood were labeled by CD4-FITC and CD25-PE, followed by 1ml freshly prepared Fixation/Permeabilization, and then stained by anti-FoxP3-PE. The data were analyzed by the BD CellQuest Pro software. The calculation formula is that the number of CD4+ T cell subsets = the number of CD4+ T cells * the percentage of CD4+ T cell subsets.

Serum cytokines (IL-2, IL-4, IL-6, IL-10, IL-17, TNF-α, and IFN-γ) were detected by magnetic bead-based multiplex immunoassay using Human Th1/Th2/Th17 subgroup test kit (Jiangxi Cellgene Biotechnology Co., Ltd China) according to the manufacturer’s recommendations. The Bio-Plex 200 reader was used to acquire the data as Median Fluorescence Intensity (MFI) and concentration (pg/ml).

Imaging examinations included ultrasonography, computerized tomography (CT), enhanced CT, magnetic resonance imaging (MRI), and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Pathological and immunohistochemical examinations were carried out on 39 patients with IgG4-RD.

Statistical Analysis

Data for patient characteristics and laboratory findings were summarized as the median and interquartile range (IQR) unless otherwise stated. T-test or rank-sum test was used to compare the measurement data between groups. The chi-square test of independence was used to assess categorical variables. Spearman’s rank correlation was used to analyze the correlation between the measurement data of the patient group. ROC curve was used to analyze the correlation between serum C3 level and the affected organs, and the predictive effect was evaluated according to area under the curve (AUC). P < 0.05 indicates a statistical difference. The statistical software is R 4.0.5.

RESULTS

Patient Characteristics

A total of untreated 52 IgG4-RD patients, 30 males and 22 females (M: F 1.36:1), were enrolled in this study.
The demographic characteristics are shown in Table 1. Mean age at diagnosis was 57.4 ± 10.3 years (range 27-81). Median time from onset to diagnosis was 12 (3, 9) months.

**Organ Involvement**
In our cohort, 10 patients (19.2%) and 23 patients (44.2%) had 1 and 2 organs involved, respectively, 19 patients (36.6%) had more than 2 organs involved. The mean number of affected organs was 2.7 (range 1-8) (Table 1). Submandibular gland (30, 57.7%), lacrimal gland/orbit (21, 40.4%), lung/pleura (16, 30.8%) were the most commonly affected organs, followed by pancreas (14, 26.9%), parotid (12, 23.1%), bile duct (11, 21.2%), kidney (11, 21.2%), nasal cavity/sinuses (8, 15.4%), retroperitoneal fibrosis (4, 7.7%), and others. Notably, vaginal involvement was detected by PET/CT which showed hypermetabolic nodules in the left lateral wall in a multi-organ involved woman (Table 2).

**Atopy**
There were 11 patients (21.2%) with atopic history (Table 1). The main manifestations were asthma and rhinoconjunctivitis. The allergens were mostly pollen, wormwood, mites and dust. There was no significant difference in serum IgG4 level, absolute Th2 counts, and peripheral eosinophil counts between atopic and non-atopic patients (Table 3).

**Laboratory Examinations**
In this study, 9 patients (9/52, 17.3%) had elevated eosinophil counts. 33 patients (33/46, 71.7%) had mild-to-moderate elevated ESR with a median of 27 (15.75, 57.75) mm/h; CRP increased in 12 patients (12/40, 30.0%) with a median of 3.14 (2.81, 8.32) mg/l. There were 47 patients (47/48, 97.9%) who had elevated serum IgG4, with a median of 1300 (585.25, 1975) mg/dl. The patients with elevated IgG1, IgG2, and IgG3 were 4 (4/27, 14.8%), 12 (12/26, 46.2%), and 5 (5/27, 18.5%), respectively. Decreased C3 occurred in 21 patients (21/27, 77.8%), and 15 patients (15/27, 55.6%) had C4 reduction. Low titers of ANA were detected in 6 cases (6/50, 12.0%), 11 cases (11/50, 22.0%) with positive RF, 1 case with positive anti-smooth muscle antibody, 1 case with positive anti-MCV antibody, and the anti-ENAs were all negative (Table 4).

### Table 1 | Comparisons of clinical characteristics in patients with IgG4-RD in different studies.

| Characteristics                  | Current study | Zhang et al. (6) | Yamada et al. (7) | Wallace et al. (8) |
|----------------------------------|---------------|------------------|-------------------|-------------------|
| Number of cases (n)              | 52            | 348              | 334               | 125               |
| Age at diagnosis, mean (range)   | 57.4 (27-81)  | 53.8 (9-83)      | 63.8 (25-91)      | 55.2 (24-83)      |
| Disease duration (months)         | 12 (3-24)     | 12 (3-36)        |                   |                   |
| Male: Female                     | 1.36:1        | 1.98:1           | 1.59:1            | 1.55:1            |
| Race                             | Chinese       | Chinese          | Japanese          | 76%Caucasian      |
| Elevated serum IgG4, n (%)       | 47 (97.9)     | 285 (94.1)       | 318 (95.5)        | 52 (61.0)         |
| Serum IgG4 level (mg/dl)         | 1300 (585.25, 1975) | 766 (313, 1780) | 755 ± 642         |                   |
| Number of affected organs, mean (range) | 2.7 (1-8) | 3.2 (1-11)       | 2.3 (1-7)         |                   |
| History of atopy, n (%)          | 11 (21.2)     | 172 (49.7)b      |                   |                   |

Data are expressed as mean ± S.D., M (P25,P 75) or number (%). *Years of disease duration; bHistory of allergy.

### Table 2 | Comparisons of organ involvement in patients with IgG4-RD in different studies.

| Affected Organs                  | Current study (n=52) | Zhang et al. (6) (n=346) | Yamada et al. (7) (n=334) | Wallace et al. (8) (n=125) |
|----------------------------------|----------------------|--------------------------|---------------------------|---------------------------|
| Submandibular gland              | 30 (57.7)            | 182 (52.6)               | 242 (72.7)a               | 35 (28.0)                 |
| Parotid                          | 12 (23.1)            | 75 (21.7)                |                           | 21 (16.8)                |
| Lacrimal gland/Orbit             | 21 (40.4)            | 161 (46.5)               | 190 (57.1)                | 28 (22.4)                |
| Lung/Pleura                      | 16 (30.8)            | 97 (28.0)b               | 78 (23.4)                 | 22 (17.6)                |
| Pancreas                         | 14 (26.9)            | 133 (38.4)               | 85 (25.5)                 | 24 (19.2)                |
| Kidney                           | 11 (21.2)c           | 24 (6.9)                 | 79 (23.7)                 | 15 (12.0)                |
| Bile duct                        | 11 (21.2)            | 88 (25.4)                | 18 (5.4)                  | 12 (8.6)                 |
| Nasal cavity.Sinuses             | 8 (15.4)             | 81 (23.4)                |                           | 3 (2.4)d + 5 (4.0)f      |
| RPF                              | 4 (7.7)              | 69 (19.9)                | 83 (24.9)d               | 23 (18.4)                |
| Aorta                            | 2 (3.8)              | 33 (9.5)                 | 32 (9.6)                  | 4 (3.2)                  |
| Skin                             | 3 (5.8)              | 22 (6.4)                 | 5 (1.5)                   | 2 (1.6)                  |
| Prostate                         | 2 (3.8)              | 48 (20.9)                | 3 (0.9)                   | 7 (5.6)                  |
| Thyroid                          | 1 (1.9)              | 14 (4.0)                 |                           | 2 (1.6)                  |
| Meninges                         | 1 (1.9)              | 5 (1.4)                  |                           | 3 (2.4)                  |
| Hypophysis                       | 1 (1.9)              | 8 (2.3)                  |                           | 2 (1.6)                  |
| Mesentery                        | 1 (1.9)              | 9 (2.6)                  |                           | 2 (1.6)                  |
| Breast                           | 1 (1.9)              |                          |                           |                          |
| Vagina                           | 1 (1.9)              |                          |                           |                          |

Data are expressed as number (%). aThe data included both submandibular gland and parotid involvement; bLung; cPleura; dKidney involvement included kidney, renal pelvis, and ureter involvement; eNasal cavity; fSinuses; gThe data included both RPF and Aorta involvement; RPF, Retroperitoneal fibrosis.
TABLE 3 | Comparisons of eosinophils, Th2 and serum IgG4 level in atopic and non-atopic patients with IgG4-RD.

| Group          | Eosinophils (*10^9/l) | Th2 (cells/μl) | IgG4 (mg/dl) |
|----------------|-----------------------|----------------|--------------|
|                | N (P25, P75)          | N (P25, P75)   | N (P25, P75) |
| non-Atopy      | 41 (0.10, 0.47)       | 27 (5.35, 11.48) | 38 (408, 2120) |
| Atopy          | 11 (0.26, 0.43)       | 9 (8.61, 15.09)  | 10 (1345, 1590) |
| P-value        | 0.494                 | 0.523          | 0.790        |

TABLE 4 | Laboratory findings in patients with IgG4-RD.

| Laboratory Examination | Value |
|------------------------|-------|
| ESR (mm/h)             | 27 (15.75, 57.75) |
| Elevated ESR, n (%)    | 33 (71.7) |
| CRP (mg/l)             | 3.14 (2.81, 8.32) |
| Elevated CRP, n (%)    | 12 (30.0) |
| Elevated eosinophils, n (%) | 9 (17.3) |
| C3 < 0.79 g/l, n (%)   | 21 (77.8) |
| C4 < 0.18 g/l, n (%)   | 15 (63.6) |
| ANA positive, n (%)    | 6 (12.0) |
| RF positive, n (%)     | 11 (22.0) |
| IgG1 (mg/dl)           | 892 (675.5, 1100) |
| Elevated IgG1, n (%)   | 4 (14.8) |
| IgG2 (mg/dl)           | 669.5 (450.25, 791.75) |
| Elevated IgG2, n (%)   | 12 (46.2) |
| IgG3 (mg/dl)           | 48 (32.7, 91.4) |
| Elevated IgG3, n (%)   | 5 (18.5) |
| IgG4 (mg/dl)           | 1300 (585.25, 1975) |
| Elevated IgG4, n (%)   | 47 (97.9) |

Data are expressed as mean ± S.D. or M (P25, P75). ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; C3, Complement 3; C4, Complement 4; ANA, anti-nuclear antibody; RF, Rheumatoid factor; Ig, Immunoglobulin.

Peripheral Lymphocyte Subgroups and CD4^+ T Cell Subsets

Among the 52 IgG4-RD patients, 38 carried out the detection of peripheral lymphocyte subgroups, and 36 conducted CD4^+ T cell subsets assay (Table 5). The absolute Th1 counts were higher in patients with IgG4-RD than in HC (157.58 cells/μl vs. 130.54 cells/μl, P = 0.038), whereas, there was no difference in percentages of Th1 cells between IgG4-RD patients and HC (20.01% vs. 16.9%, P = 0.207). The absolute counts of CD3^+ T cells, CD19^+ B cells, NK cells, CD4^+ T cells, CD8^+ T cells, Th2, Th17, and Treg cells showed no significant difference between patients with IgG4-RD and HC. However, the percentages of Treg cells was lower in IgG4-RD patients as compared with HC (3.64% vs. 5.19%, P = 0.002). No difference was observed in Th1/Th2 (20.02 vs. 15.7, P = 0.063) and Th17/Treg ratio (0.27 vs. 0.18, P = 0.095) between IgG4-RD patients and HC (Figure 1).

Cytokines

Serum cytokines were measured in 25 of the 52 patients. Compared with HC, the levels of serum IL-4, IL-6, IL-10, IL-17, TNF-α, and IFN-γ were statistically higher in patients with IgG4-RD (P < 0.001). There was no significant difference in IL-2 levels between IgG4-RD patients and HC (Figure 1).

Correlation Analysis

Serum IgG4 level was positively correlated with the number of involved organs (r = 0.319, P = 0.027), eosinophil counts (r = 0.432, P = 0.002), and ESR (r = 0.324, P = 0.028) in patients with IgG4-RD, and negatively correlated with the levels of serum C3 (r = -0.626, P < 0.001), C4 (r = -0.586, P = 0.001), IgM (r = -0.516, P < 0.001), and IgA (r = -0.406, P = 0.009). There was no correlation between serum IgG4 level and Th17/Treg ratio (Figure 2). Serum C3 level was a predictor of lung/pleura and kidney involvement in IgG4-RD patients. ROC test indicated the possibility of lung/pleura involvement when C3 was less than 0.545 g/l (AUC = 0.796, P = 0.014) and kidney involvement when C3 was less than 0.545 g/l (AUC = 0.788, P = 0.014).

TABLE 5 | Lymphocyte subgroups and CD4^+ T cell subsets in patients with IgG4-RD.

| Lymphocyte subsets   | CD3^+ T cells/μl | CD19^+ B cells/μl | CD4^+ T cells/μl | CD8^+ T cells/μl | Th1/Th2 | Th17/Treg |
|----------------------|------------------|------------------|-----------------|-----------------|---------|-----------|
| CD3^+ T (cells/μl)   | 1395.95 ± 540.92 | 158 (116, 218.75) |
| CD19^+ B (cells/μl)  | 251.78 (167.25, 303.5) |
| CD4^+ T (cells/μl)   | 824.77 (567.25, 1080.75) |
| CD8^+ T (cells/μl)   | 396 (306.25, 590.99) |
| Th1 (cells/μl)       | 157.58 (105.7, 220.79) |
| Th1 (%)              | 20.01 (14.26, 24.20) |
| Th2 (cells/μl)       | 7.61 (5.64, 11.55) |
| Th2 (%)              | 0.99 (0.77, 1.27) |
| Th2 (%)              | 0.99 (0.77, 1.27) |
| Th17 (cells/μl)      | 7.71 (4.32, 11.04) |
| Th17 (%)             | 1.00 (0.66, 1.42) |
| Treg (cells/μl)      | 29.74 (23.84, 42.39) |
| Treg (%)             | 3.64 (3.17, 5.28) |
| Th17/Treg            | 0.27 (0.15, 0.42) |

Data are expressed as mean ± S.D. or M (P25, P75). Lymphocyte subgroups (n=38) included CD3^+ T, CD19^+ B, NK, CD4^+ T, CD8^+ T; CD4^+ T cell subsets (n=36) included Th1, Th2, Th17, Treg; HC, healthy controls (n=50); *Percentages of Th1 in CD4^+ T cells; †Percentages of Th2 in CD4^+ T cells; §Percentages of Th17 in CD4^+ T cells; ¶Percentages of Treg in CD4^+ T cells.
Serum IL-10 was uncorrelated with Treg cells \((P = 0.298)\), but positively correlated with IL-4, TNF-\(\alpha\), and IFN-\(\gamma\) \((P \leq 0.001)\) (Figure 2).

**DISCUSSION**

Our study described the demographic characteristics, laboratory examinations, and imaging features of 52 IgG4-RD patients, and focused on the analyses of T lymphocyte subsets and cytokine levels. Consistent with other reports (7, 8, 10, 11), the majority of patients in our cohort were middle aged to elderly Chinese men. Our findings confirmed that IgG4-RD often involved multiple organs successively or simultaneously, and \(\geq 2\) organs accounted for 80.8% of the cases. Submandibular gland, lacrimal gland/orbit, lung/pleura, pancreas, parotid, bile duct, and kidney were commonly involved organs, with less common ones including nasal cavity/sinuses, retroperitoneal fibrosis, skin, prostate, aorta, thyroid, hypophysis, meninges, mesentery, breast, and vagina.

Patients with elevated serum IgG4 levels accounted for 97.9% of the cases in our research, consistent with the findings of Yamada (7) and Lin (10). However, in the studies by Wallace (8) and Campochiaro (12), only 51% and 73% of the patients had elevated serum IgG4. This distinction may be related to the differences of region and ethnicity. Elevated serum IgG4 is a typical clinical manifestation of IgG4-RD, but elevated IgG4 only occurs in 51-98% of the patients, especially in Asian. Thus, it is imperative to integrate clinical, serological, radiological, and pathological features to make a comprehensive diagnosis of IgG4-RD.

IgG1, IgG2, and IgG3 increased to varying degrees in some patients, of which IgG2 increase accounted for 46.2% of the patients, significantly higher than that of IgG1 and IgG3. A retrospective study found that when IgG2 > 5.3g/l, the sensitivity of orbital IgG4-RD diagnosis can reach 80% and the specificity can reach 91.7%. The combined detection of serum IgG2 and IgG4 can be used as a new reference index for the diagnosis of IgG4-RD (13).

Our study found no significant difference in peripheral eosinophil counts between atopic and non-atopic patients. The absolute eosinophil counts were positively correlated with serum IgG4 level, consistent with the findings of Della-Torre (14). Regardless of whether the patient had an atopic disease, the histological specimens of the affected tissues tended to increase eosinophils. The evidence demonstrated that the elevated eosinophil counts seem not to be related to the presence of atopic diseases, but inherent to IgG4-RD itself (14–16).

Many similarities exist between IgG4-RD and allergic diseases, such as the increase of eosinophil counts, IgE, IgG4, and Th2 associated cytokines (IL-4, IL-5, and IL-13). However, no significant difference in serum IgG4 level, absolute Th2
FIGURE 2 | Correlation analyses of laboratory findings in patients with IgG4-RD. (A–G) Serum IgG4 level was positively correlated with ESR, the number of involved organs, and Eos, and negatively correlated with C3, C4, IgM, and IgA. (H) There was no correlation between serum IgG4 level and Th17/Treg ratio in IgG4-RD patients. (I–L) Serum IL-10 was uncorrelated with Treg, but positively correlated with IL-4, IFN-γ and TNF-α. Eos, eosinophils; C3, Complement 3; C4, Complement 4; Ig, Immunoglobulin.

FIGURE 3 | The predictive performance of serum C3 level in lung/pleura and kidney involvement in patients with IgG4-RD. (A) ROC test indicated the possibility of lung/pleura involvement when C3 was less than 0.570 g/l (AUC=0.788, P=0.014). (B) There might be kidney involvement when C3 was less than 0.545 g/l (AUC=0.796, P=0.014). C3, Complement 3; ROC, receiver operator characteristic; AUC, area under the curve; Kidney involvement included kidney, renal pelvis, and ureter involvement.
counts and eosinophil counts between atopic and non-atopic patients was found in our patient cohort. Some scholars have also suggested that IgG4-RD and allergic disorders are not clinical manifestations of a single disease, but rather distinct disease processes that both involve type 2 immune activation. In Mattoo’s study (15, 17), only about 30% of IgG4-RD patients had an allergic history, while CD4+GATA3+ Th2 cells in the affected tissues were relatively sparse. Furthermore, another important study observed the expression of IL-4 mRNA increased in IgG4-RD affected tissues, and yet GATA3+ Th2 mRNA decreased, indicating that IL-4 was probably produced by non-Th2 cells (18). However, some studies showed the opposite conclusion. In IgG4-related Sclerosing Cholangitis and type 1 Autoimmune Pancreatitis (IgG4-SC/AIP) and Chronic Periarteritis (CP) patients, a dominant infiltration of GATA3+ Th2 cells were observed in the affected tissues (19, 20). With the further understanding of IgG4-RD, the role of Th2 cells in the pathogenesis will eventually be revealed.

The absolute Th1 counts were significantly increased in our study, which has also been reported in prior research (21). CD4+GZMA+IFN-γ CTLs were the most abundant infiltrating T lymphocytes in the IgG4-RD affected tissues, which could synthesize and secrete profibrotic cytokines of IL-1β, TGF-β1 and IFN-γ, as well as release cell-lysing substances such as perforin, granzyme A, and granzyme B (17, 18, 22). Elevated Th1 cells in our research were probably part of CD4+GZMA+IFN-γ CTLs which have been misclassified as Th1 cells. CD4+ CTLs are not specific to IgG4-RD and also expand in the diseases of inflammatory bowel disease, systemic sclerosis, and rheumatoid arthritis, suggesting that these cells may play a role in the process of chronic inflammation and fibrotic disorder (9, 23, 24).

Treg cells play a vital role in maintaining immune homeostasis and autoimmune tolerance. Quantitative and functional defects of Treg cells have been described among a variety of autoimmune diseases (25–27). Intensive studies also have reported that the imbalance of Th17/Treg has a relationship with some autoimmune diseases (28–30). However, we found no difference in absolute Treg cells and Th17/Treg ratio between IgG4-RD patients and HC, consistent with Mattoo’s reports (22). In their study, 15 IgG4-RD patients received rituximab for 3–4 months, with dramatic clinical improvement, accompanied by a greater than 50% reduction in circulating CD4+ CTLs numbers and tissue fibrosis improved. Nonetheless, there was minimal impact on the number of circulating Treg cells. Based on the research above, it was suggested that Treg cells may not play a dominant role in the pathogenesis of IgG4-RD.

Cytokines are important small molecules in signal transmission between immune cells. As pro-inflammatory cytokines, the mild increases of serum IL-6, IL-17, TNF-α, and IFN-γ were in accordance with the mild inflammatory conditions in IgG4-RD. The slight increase of IL-4 may be related to the increase of Th2 (T follicular helper 2) cells (31, 32). IL-10, a representative anti-inflammatory cytokine, is mainly secreted by Treg cells and plays an important role in maintaining immune homeostasis. It was also mildly elevated and positively correlated with IL-4, TNF-α, and IFN-γ, but uncorrelated with Treg cells. It is assumed that the source of increased IL-10 does not exclude the participation of the other important cells such as Th17 cells (33). IL-10 may also play a pro-inflammatory role in IgG4-RD by promoting the survival and proliferation of B cells, production of antibodies, and immunoglobulin class switching.

The limitations of our study include the fact that it was a retrospective study with a relatively small sample size, and a few of the cases have a certain degree of data missing. In addition, due to the retrospective nature, we failed to investigate some other important data such as plasmablasts, Th cells, serum IgE, TGF-β, and disease activity assessed by IgG4-RD responder index (R1).

In conclusion, IgG4-RD is more common in middle aged and elderly men, and submandibular and lacrimal glands are the most frequently involved sites. Elevated Th1 cells probably play an important role in tissue lesion and fibrosis. Conversely, Th2 cells were unlikely to be linked to the pathogenesis of IgG4-RD. The quantitative defects of Treg cells and the imbalance of Th17/Treg may not be involved in the disease. Th17 cells, an important subset of CD4+ T cells, which play an essential role in tissue lesion and fibrosis. Conversely, Th2 cells were unlikely to be linked to the pathogenesis of IgG4-RD. The quantitative defects of Treg cells and the imbalance of Th17/Treg may not be involved in the disease. Th17 cells, an important subset of CD4+ T cells, which play an essential role in tissue lesion and fibrosis. Conversely, Th2 cells were unlikely to be linked to the pathogenesis of IgG4-RD. The quantitative defects of Treg cells and the imbalance of Th17/Treg may not be involved in the disease. Th17 cells, an important subset of CD4+ T cells, which play an essential role in tissue lesion and fibrosis. Conversely, Th2 cells were unlikely to be linked to the pathogenesis of IgG4-RD. The quantitative defects of Treg cells and the imbalance of Th17/Treg may not be involved in the disease.

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of the second hospital of Shanxi Medical University (Shanxi, China). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

YY designed the study, analyzed the data, and wrote the manuscript. LS, SY and YL participated in the sample and data collection. CW provided Pathological specimen data and revised the manuscript. JL provided the healthy control data and revised the manuscript. CW designed the study and revised the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (81971543, 81471618) and the Key Research and Development Projects of Shanxi Province, China (201803D31119).
REFERENCES

1. Wallace ZS, Perugino C, Matra M, Deshpande V, Sharma A, Stone JH. IgG4-Related Disease. *Clin Chest Med* (2019) 40(3):583–97. doi: 10.1016/j.ccm.2019.05.00

2. Lanzillotta M, Mansueto G, Della-Torre E. Advances in the Diagnosis and Management of IgG4 Related Disease. *BMJ* (2020) 369:m1067. doi: 10.1136/bmj.m1067

3. Della-Torre E, Lanzillotta M, Dogliani C. Immunology of IgG4-Related Disease. *Clin Exp Immunol* (2015) 181(2):191–206. doi: 10.1111/cei.12641

4. Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire J-F, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. *Ann Rheum Dis* (2020) 79(1):77–87. doi: 10.1136/annrheumdis-2019-216561

5. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, et al. Environmental Exposures and Atopy in IgG4-Related Disease: A Revised Nomenclature for Allergy. An EAACI Position Statement From the EAACI Nomenclature Task Force. *Allergy* (2001) 56(9):813–24. doi: 10.1034/j.1398-9995.2001.1-00001.x

6. Zhang P, Zhao J, Wang M, Feng R, Liu X, Lai Y, et al. Clinical Characteristics of 346 Cases in IgG4-Related Diseases. *Chin J Intern Med* (2017) 56:644–9. doi: 10.3760/cma.j.issn.0578-1426.2017.09.005

7. Yamada K, Yamamoto M, Sacki T, Mizushima I, Matsuji S, Fujisawa Y, et al. New Clues to the Nature of Immunoglobulin4-Related Disease: A Retrospective Japanese Multicenter Study of Baseline Clinical Features of 334 Cases. *Arthritis Res Ther* (2017) 19:262. doi: 10.1186/s13075-017-1467-x

8. Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kikutowa M, Pillai S, et al. IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients. *Arthritis Rheumatol* (2015) 67(9):2466–75. doi: 10.1002/art.39205

9. Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, et al. CD4 + NKGD2+ T Cells in Crohn’s Disease: Mediate Inflammatory and Cytotoxic Responses Through MICA Interactions. *Gastroenterology* (2007) 132:2346–58. doi: 10.1053/j.gastro.2007.03.025

10. Lin W, Lu S, Chen H, Wu Q, Fei Y, Li M, et al. Clinical Characteristics of Immunoglobulin G4-Related Disease: A Prospective Study of 118 Chinese Patients. *Rheumatol (Oxford)* (2015) 54(11):1982–90. doi: 10.1093/rheumatology/kew203

11. Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K, et al. IgG4-Related Disease: Dataset of 235 Consecutive Patients. *Med (Baltimore)* (2015) 94(15):e680. doi: 10.1097/MD.0000000000000680

12. Campochiaro C, Ramirez GA, Bozzolo EP, Lanzillotta M, Berti A, Baldisera E, et al. IgG4-Related Disease in Italy: Clinical Features and Outcomes of a Large Cohort of Patients. *Scand J Rheumatol* (2016) 45(2):135–45. doi: 10.3109/03009742.2015.1055796

13. Chan ASY, Mudhar H, Shen SY, Lang SS, Fernando M, Hilmy MH, et al. Serum IgG2 and Tissue IgG2 Plasma Cell Elevation in Orbital IgG4-Lated Disease (IgG4-RD): Potential Use in IgG4-RD Assessment. *Br J Ophthalmol* (2017) 101(1):1576–82. doi: 10.1136/bjophthalmol-2017-310148

14. Della-Torre E, Mattoo H, Mahajan VS, Carruthers M, Pillai S, et al. Stone JH. Prevalence of Atopy, Eosinophilia, and IgE Elevation in IgG4-Related Disease. *Allergy* (2014) 69(2):269–72. doi: 10.1111/all.12320

15. Mattoo H, Della-Torre E, Mahajan VS, Stone JH, Pillai S. Circulating Th2 Memory Cells in IgG4-Related Disease are Restricted to a Defined Subset of Subjects With Atopy. *Allergy* (2014) 69(3):399–402. doi: 10.1111/all.12342

16. Michailidou D, Schwartz DM, Mustelin T, Hughes GC. Allergic Aspects of IgG4-Related Sclerosing Cholangitis. *J Hepatol* (2013) 59(5):1039–64. doi: 10.1016/j.jhep.2013.06.016

17. Maehara T, Mattoo H, Ohta M, Mahajan VS, Moriyama M, Yamauchi M, et al. Circulating Th2 Cells in IgG4-Related Disease. *Arthritis Rheumatol* (2015) 67(9):2466–75. doi: 10.1002/art.39205

18. Chemin K, Gerstner C, Malmström V. Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis. *Front Immunol* (2019) 10:353. doi: 10.3389/fimmu.2019.00353

19. Mizui M, Tsokos GC. Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus. *Front Immunol* (2018) 9:786. doi: 10.3389/fimmu.2018.00786

20. Bilate AM, Laflaife J. Induced CD4+Foxp3+ Regulatory T Cells in Immune Tolerance. *Arnost Rev Immunol* (2012) 30:733–58. doi: 10.1146/annurev-immunol-020711-075043

21. Okazaki K, Uchida K, Ohana M, Nakase H, Uose S, Inai M, et al. Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus. *Eur J Immunol* (2015) 45:102376. doi: 10.1002/eji.2015102376

22. Noack M, Miossec P. Th17 and Regulatory T Cell Balance in Autoimmune and Inflammatory Diseases. *Autoimmun Rev* (2014) 13(6):668–77. doi: 10.1016/j.autrev.2013.12.004

23. Wu R, Li N, Zhao X, Ding T, Xue H, Gao C, et al. Low-Dose Interleukin-2: Biology and Therapeutic Prospects in Rheumatoid Arthritis. *Autoimmun Rev* (2020) 19(10):102645. doi: 10.1016/j.autrev.2020.102645

24. Shan J, Jin H, Xu Y. T Cell Metabolism: A New Perspective on Th17/Treg Cell Imbalance in Systemic Lupus Erythematosus. *Front Immunol* (2020) 11:1027. doi: 10.3389/fimmu.2020.01027

25. Akiyama M, Yasuoka H, Yamaoka K, Suzuki K, Kaneko Y, Kondo H, et al. Enhanced IgG4 Production by Follicular Helper 2 T Cells and the Involvement of Follicular Helper 1 T Cells in the Pathogenesis of IgG4-Related Disease. *Arthritis Rheum Dis* (2017) 18:167. doi: 10.1002/art.41024

26. Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y, et al. Number of Circulating Follicular Helper 2 T Cells Correlates With IgG4 and Interleukin-4 Levels and Plasmaestatin Numbers in IgG4-Related Disease. *Arthritis Rheumatol* (2015) 67(9):2476–81. doi: 10.1002/art.39209

27. Bedke T, Muscate F, Soukou S, Gagliani N, Huber S. IL-10-Producing T Cells and Their Dual Functions. *Semin Immunol* (2019) 44:101335. doi: 10.1016/j.smim.2019.101335

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yang, Wang, Shi, Yang, Liu, Luo and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.